Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Oxaliplatin 149Fluorouracil 136Gemcitabine 117Bevacizumab 115Leucovorin 106Specimen Handling 105Capecitabine 95pembrolizumab 89Magnetic Resonance Spectroscopy 83Cisplatin 79Nivolumab 77Irinotecan 71durvalumab 63Cetuximab 62Paclitaxel 60Biopsy 60130-nm albumin-bound paclitaxel 60atezolizumab 44Radiotherapy 44Taxes 36Carboplatin 36Albumin-Bound Paclitaxel 36Folfox protocol 35Drug Therapy 31Cyclophosphamide 30lenvatinib 29dehydroftorafur 28tislelizumab 27sintilimab 27Radiation 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytochrome P-450 CYP2B6 × Gastrointestinal × 90 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡